[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Recombinant human tissue-type plasminogen activator (rt-PA) was successfully given via central vein to a 1.7 year old child with angiographically documented septic vena cava superior thrombosis Thrombolytic therapy with rt-PA was started with 0.2 mg/kg as a slow bolus injection followed by an infusion of 0.8 mg/kg over 60 min. rt-PA was applicated 12 hours after an urokinase bolus in a dosage of 8000 E/kg and heparin infusion of 500 E/kg/die. No clinical side effects or alterations in the plasmatic coagulation profile were noted. The prompt clinical response suggests that the use of rt-PA in thrombotic disease should be investigated further to establish efficacy, dosing guidelines, complication rates, and contraindications in childhood.
Schranz
D
D
Universitätskinderklinik, Mainz.
Haugwitz
D
D
Zimmer
B
B
Schumacher
R
R
D004359:Drug Therapy, Combination; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D008297:Male; D010288:Parenteral Nutrition / Q000009:adverse effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage; D014683:Vena Cava, Superior
D011994:Recombinant Proteins; D006493:Heparin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Erfolgreiche Lysebehandlung einer septischen Thrombose der Vena cava superior mit rekombinantem Gewebe-Plasminogen-Aktivator.